Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

Breakthrough in diabetes treatment! The US FDA approves Ozempic for reducing kidney disease risk in diabetic patients. Learn ...

Singer Avery developed osteoporosis after using Ozempic for a year to lose weight. She warns against its misuse, highlighting ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

FDA expands Ozempic label to include kidney disease benefits in type 2 diabetes patients. Novo Nordisk's drug can now be ...

Novo Nordisk said the Food and Drug Administration approved the diabetes-drug Ozempic to be used to help kidney-disease patients. Ozempic, or semaglutide, can now be used to reduce the risk of ...

Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Novo Nordisk’s NVO shares gained 8.5% on Friday after the company announced positive top-line data from an early to mid-stage ...